Allergan PLC. (NYSE:AGN) had its price target decreased by investment analysts at Royal Bank Of Canada from $285.00 to $277.00 in a report released on Monday. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 35.35% from the stock’s previous close.

Several other equities research analysts have also recently commented on AGN. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Thursday, June 8th. Citigroup Inc. reiterated a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a report on Wednesday, September 20th. Mizuho reduced their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Allergan PLC. in a report on Friday, June 16th. They issued a “neutral” rating and a $231.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target for the company in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. has a consensus rating of “Buy” and a consensus price target of $272.94.

Shares of Allergan PLC. (AGN) opened at 204.65 on Monday. The company has a market cap of $68.42 billion, a price-to-earnings ratio of 6.24 and a beta of 1.18. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The stock has a 50 day moving average of $229.79 and a 200-day moving average of $236.07.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, analysts forecast that Allergan PLC. will post $16.26 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This article was published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/25/allergan-plc-agn-given-new-277-00-price-target-at-royal-bank-of-canada.html.

Several hedge funds and other institutional investors have recently modified their holdings of AGN. Howard Hughes Medical Institute purchased a new stake in Allergan PLC. in the second quarter worth approximately $103,000. Jacobi Capital Management LLC lifted its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after purchasing an additional 22 shares during the last quarter. JNBA Financial Advisors lifted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after purchasing an additional 12 shares during the last quarter. Massey Quick & Co. LLC lifted its position in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after purchasing an additional 385 shares during the last quarter. Finally, Pacific Center for Financial Services lifted its position in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after purchasing an additional 475 shares during the last quarter. 82.02% of the stock is owned by institutional investors.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.